Skip to main content

Table 3 Base case results of cost-effectiveness analysis (both direct and indirect costs were considered in the analysis)

From: Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

Direct comparison Total cost QALYs Incremental cost Incremental QALYs ICER
    Agomelatine vs. comparator Agomelatine vs. comparator  
Agomelatine €5,434 1.461 - - -
Venlafaxine €5,420 1.436 €14 0.026 €547/QALY
Sertraline €5,650 1.427 - €215 0.034 Agom. dominant
Escitalopram €5,462 1.447 - €28 0.015 Agom. dominant
Fluoxetine €5,563 1.431 - €129 0.030 Agom. dominant
Generic Venlafaxine €5,397 1.436 €37 0.026 €1,446/QALY
Generic Sertraline €5,600 1.427 -€166 0.034 Agom. dominant
Generic Escitalopram €5,386 1.447 €48 0.015 €3,303/QALY
Generic Fluoxetine €5,508 1.431 -€74 0.030 Agom. dominant
  1. QALY Quality Adjusted Life Year.
  2. ICER Incremental cost effectiveness ratio.